Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Nov 13;7:15443. doi: 10.1038/s41598-017-15749-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

WBSCR22 knockdown increased oxaliplatin sensitivity in vivo. The mice in the treatment groups were treated with oxaliplatin by intraperitoneal injection, on a schedule of two injections every week at 7.5 mg/kg per injection. The mice in the control groups were injected with solvent (aqueous glucose 5% solution [5% GS]). (A) Macroscopic images of xenografted tumors excised at day 25. (B) The relative mean tumor volume (RMTV) curve of the Caco-2 shRNA1 xenograft models. The data were expressed as the mean ± SE. *p < 0.05, (Caco-2 shRNA1 + oxaliplatin [treatment group] vs. Caco-2 shRNA1 + 5% GS [control group]). (C) The relative mean tumor volume (RMTV) curve of the Caco-2 shCon xenograft models. The results were expressed as the mean ± SE. (D) The mean tumor volume (MTV) curve of the Caco-2 shCon and shRNA1 xenograft models in the control groups. The data were expressed as the mean ± SE. (E) Immunohistochemical analysis of WBSCR22 protein in the excised tumor tissues from the shCon and shRNA1 control groups (×40, ×200). (F) Immunohistochemical analysis of cleaved caspase-3 in the excised tumor tissues from the shCon and shRNA1 treatment groups (×200). The data were expressed as the mean ± SD. ***p < 0.001 (shRNA1 + oxaliplatin [treatment group] vs. shCon + oxaliplatin [treatment group]).